Nabriva Therapeutics AG (NBRV) Receiving Favorable News Coverage, Report Shows
Headlines about Nabriva Therapeutics AG (NASDAQ:NBRV) have trended positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Nabriva Therapeutics AG earned a coverage optimism score of 0.28 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have effected Accern’s scoring:
- Nabriva Therapeutics AG (NASDAQ:NBRV) Expected to Announce Quarterly Sales of $1.34 Million (americanbankingnews.com)
- Nabriva Therapeutics AG (NASDAQ:NBRV) Major Shareholder Hbm Healthcare Investments (Ca Sells 57,175 Shares (americanbankingnews.com)
- Zacks: Analysts Anticipate Nabriva Therapeutics AG (NASDAQ:NBRV) to Announce -$0.57 Earnings Per Share (americanbankingnews.com)
- Nabriva Therapeutics AG (NBRV) Rating Lowered to Sell at Zacks Investment Research (americanbankingnews.com)
- Nabriva Therapeutics Appoints Francesco Maria Lavino as Chief Commercial Officer (finance.yahoo.com)
Nabriva Therapeutics AG (NASDAQ:NBRV) traded down 0.19% during midday trading on Monday, reaching $10.50. 1,020 shares of the company were exchanged. The firm’s market cap is $28.57 million. The firm’s 50-day moving average is $9.87 and its 200-day moving average is $9.52. Nabriva Therapeutics AG has a one year low of $3.52 and a one year high of $12.75.
A number of equities analysts have recently commented on NBRV shares. Needham & Company LLC reissued a “buy” rating and issued a $15.00 target price on shares of Nabriva Therapeutics AG in a research note on Monday, March 27th. HC Wainwright reaffirmed a “buy” rating on shares of Nabriva Therapeutics AG in a report on Friday, May 12th. Cantor Fitzgerald set a $16.00 price target on shares of Nabriva Therapeutics AG and gave the company a “buy” rating in a report on Monday, June 5th. ValuEngine raised shares of Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. Finally, Wedbush reaffirmed an “outperform” rating and set a $13.00 price target on shares of Nabriva Therapeutics AG in a report on Monday, May 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. Nabriva Therapeutics AG presently has a consensus rating of “Buy” and a consensus price target of $15.29.
ILLEGAL ACTIVITY WARNING: This story was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.watchlistnews.com/nabriva-therapeutics-ag-nbrv-receiving-favorable-news-coverage-report-shows/1445233.html.
In related news, major shareholder Hbm Healthcare Investments (Ca sold 2,695 shares of the company’s stock in a transaction on Friday, July 7th. The shares were sold at an average price of $10.52, for a total transaction of $28,351.40. Following the completion of the transaction, the insider now directly owns 2,569,315 shares in the company, valued at approximately $27,029,193.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director George Harrison Talbot sold 325 shares of the company’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $100.56, for a total transaction of $32,682.00. Following the transaction, the director now owns 3,854 shares of the company’s stock, valued at $387,558.24. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 126,778 shares of company stock valued at $1,453,057.
Nabriva Therapeutics AG Company Profile
Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic for systemic administration in humans. The Company develops both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP).
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with Analyst Ratings Network's FREE daily email newsletter.